IPEC Americas Guidelines
- 202106-02_Pharmeuropa_33.2_Nitrosamine Commenting_Final
- IPEC-Americas_USP_Response_IPA_intent_revise_FINAL
- IPEC-Americas_FDA-2020-D-2016_Policy_for_Testing_Alcohol_FINAL_4-16-2021
- IID GDUFA III – IPEC-Americas FINAL_share FDA
- ANSES Report -List of 37 Food Additives (English) (Word Version)
- E171 – Overview of EFSA Opinion (5-18-2021)
- Recommendations for Responding to Requests from USP for Samples Final
- IPEC-Americas_USP_Response GSP GC Prospectus Final
- IPEC-Americas_USP comments_Open_Forum_Feb 2021
- 2021_March FDA_Reports_Announcements
- IPEC-Americas_USP_Response_232_cutaneous_Final
- IPEC-Americas_USP_Response_oleyl_oleate_final
- 2021 CDE Tech Guide for CMC Changes of Innovative Drugs during Clinical Trials
- IPEC-PQG GMP Guide 2017_Final FR_format
- IPEC-Americas 2020 Year in Review
- USP Response to IA endorsement of IFAC comments
- USP response to IA Deferral of rev to Maltol monograph PF 46(2)
- IPEC-Americas_USP_Response_Glucose_Liquid_Final
- Pharmaceutical Lactose used in oral preparations is a low risk excipient
- Attachment A4 Drug Marketing Authorization Holder Change Dossier Requirements
- Attachment 3 Policy Interpretations of Provisions for Post-approval Changes of Medicinal Product
- Attachment 2 Implementation PAC
- Attachment A3 Provisions for Post-approval Changes of Medicinal Product
- IPEC-Americas endorsement of IFACs comments on GCs 2740_2800_2750
- 2021_Feb FDA_Reports_Announcements
- Editor Response to NaCMC letter to editor
- IPEC_2021 NaCMC letter to the editor FINAL LETTER 18 Jan 2021
- 2021-02-17 E171 – Advocacy Brochure-1